Literature DB >> 12063093

Anti-inflammatory effects of cerebrocrast in a model of rat paw edema and on mononuclear THP-1 cells.

Andis Klegeris1, Evaldas Liutkevicius, Gene Mikalauskiene, Gunars Duburs, Patrick L McGeer, Vija Klusa.   

Abstract

Cerebrocrast (IOS 1.1212; 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid di(2-propoxyethyl) diester) is a novel derivative of 1,4-dihydropyridine, which does not antagonize Ca(2+) influx in neuronal tissues. Since several classical dihydropyridines possess anti-inflammatory properties, we first studied the effects of cerebrocrast in a model of rat paw edema induced by carrageenan. Cerebrocrast had a preventative effect in this model of inflammation, with maximal activity (32-45% inhibition) in the 0.1-0.25 mg kg(-1) range. It was ineffective when added after the injection of carrageenan. Subsequent in vitro experiments showed that cerebrocrast in the micromolar range inhibited secretion of interleukin-1 beta, interleukin-6 and neurotoxic products by cells of the human monocytic THP-1 line while failing to affect secretion of tumor necrosis factor (TNF-alpha). It also lacked any direct neuroprotective effect against toxic secretions from stimulated THP-1 cells. The data obtained suggest that cerebrocrast may be useful not only in various inflammatory disorders of peripheral tissues, but also in treating neurodegenerative diseases, where inflammatory mechanisms in general and microglial activation, in particular, are thought to play an important role.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063093     DOI: 10.1016/s0014-2999(02)01262-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice.

Authors:  Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Doyle Ray Moore; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.